Sharemaestro company-news research for Gilead Sciences, Inc. (GIS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
GER
Germany
Measured evidence
Company news sentiment
GIS news sentiment
Gilead Sciences, Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
Weighted tone59Neutral is 50
Constructive news tone
77/100 evidence confidence
100% direct company focus
12 current stories across 1 publishers
Current company news
News confirmed by price
Constructive news tone is drawn from 12 fresh independent stories, including 12 company-specific items across 1 publishers.
Latest source headline Why Gilead Sciences (GILD) Is Back In The Spotlight finance.yahoo.com · 13 Aug 2026 09:11What supports the read
12 current stories are mapped specifically to GIS.
Cross-story agreement is 81/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
59/100
Weighted toneConstructive news tone
77/100
Evidence confidencesolid confidence
100%/100
Company focus12 direct stories
81/100
Evidence agreement19/100 dispersion
News history
Tone and story flow over 21 days
24 Jul03 Aug13 Aug
Weighted toneStory volumeNeutral 50
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Sample depth100
10.58 effective storiesSource breadth20
1 independent publishersDirect relevance100
company-specific evidence shareFreshness80
recency-weighted evidenceAgreement81
cross-story consistencySource independence0
lower publisher concentrationPrice context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
Sentiment-trend disagreementPositive but stretched
News subjects
What is shaping the score
Earnings695 stories · 42%
Deals and strategy612 stories · 17%
Market update582 stories · 17%
Regulatory and legal691 stories · 8%
Capital return391 stories · 8%
Guidance481 stories · 8%
Source mix
Where the evidence comes from
finance.yahoo.com6112 stories · 100%
Recurring subjects
Subjects appearing most often
Earnings7Biotech6Oncology5Fda Approval3Share Price2Price Target2Pharmaceuticals2Earnings Per Share2Clinical Trials2Translational Research1
Earlier readings
How the score has changed
ConstructiveBalanced or withheldCautious
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
#139Tone
finance.yahoo.comDirect company coverage
Why Gilead Sciences (GILD) Is Back In The Spotlight
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur
BiopharmaDividendsEarningsOncologyShare PriceShare Buyback
- Published
- 13 Aug 2026 09:11
- Catalyst
- Capital return
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#284Tone
finance.yahoo.comDirect company coverage
5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management credited commercial execution and new product launches—including Trodelvy in breast cancer and Livdelzi in liver disease—for boosting results. CEO Daniel O'Day highlighted, "Quarterly PrEP sales doubled year-over-year, exceeding $1 billion for the first time," underscoring the impact of portfolio expansion. T
EarningsFda ApprovalGuidanceHivOncologyRevenue Growth
- Published
- 13 Aug 2026 04:21
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#363Tone
finance.yahoo.comDirect company coverage
Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses on translational research to speed up biomarker discovery and support precision oncology development. The AI tools are intended to help standardize and accelerate analysis of tumor samples across Gilead's oncology pipeline. Gilead is not the only company leaning into AI to reshap
AIBiotechDrug DiscoveryOncologyPartnership
- Published
- 12 Aug 2026 18:13
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#424Tone
finance.yahoo.comDirect company coverage
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Collaboration revenues were zero compared with $3.2 million a year earlier. Tango shares were down 4.8% on Tuesday, likely due to investor disappointment over the earnings miss. Higher operating expenses weighed on the result. TNGX's Q2 Results in Detail In the absence of a marketed product, Tango has no regular source of income. The company instead reports colla
BiotechClinical TrialsEarningsEarnings Per ShareOncology
- Published
- 12 Aug 2026 14:46
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#573Tone
finance.yahoo.comDirect company coverage
3 Healthcare Stocks with Open Questions
3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points. Regardless of these results, investors must exercise caution as many businesses in this space are subject to heavy regulation that can influence their earnings potential. With that said, here are three healthcare stocks we're steering clear of.
EarningsEarnings Per ShareFree Cash FlowHealthcareRegulation
- Published
- 12 Aug 2026 02:53
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#653Tone
finance.yahoo.comDirect company coverage
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program under the companies' 2022 collaboration agreement. The option exercise triggers a $10 million payment to MacroGenics. The licensed program incorporates MacroGenics' TRIDENT® platform and is directed against two undisclosed targets
BiotechCancerLicensingMilestone Payments
- Published
- 11 Aug 2026 20:05
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#786Tone
finance.yahoo.comDirect company coverage
J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?
Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum remains supportive. When a stock trades above both averages, investors generally interpret it as evidence that buying interest is strong enough to keep the shares above their medium- and long-term trend levels.Zacks Investment Research Image Source: Zacks Investment Research This strong share price performa
EarningsInnovative MedicineLitigationMedtechPatent ExpirationShare Price
- Published
- 11 Aug 2026 13:12
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#869Tone
finance.yahoo.comDirect company coverage
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the nominees for the 2026 Prix Galien USA Awards in the "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases" categories. Winners will be honored at the Prix Galien USA Awards Ceremony on October 29, 2026, at the American Museum of Natural History in New York City.logo "We are proud to recog
BiotechFda ApprovalPharmaceuticalsRare Diseases
- Published
- 11 Aug 2026 13:00
- Catalyst
- Regulatory and legal
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#961Tone
finance.yahoo.comDirect company coverage
Nucleai Advances AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration
Collaboration demonstrates how AI-powered Tissue Intelligence is transforming biomarker discovery, translational research, and precision oncology development. TEL AVIV, Israel, August 11, 2026--(BUSINESS WIRE)--Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understandi
AI HealthcareBiomarker DiscoveryPharmaceutical CollaborationPrecision OncologyTranslational Research
- Published
- 11 Aug 2026 13:00
- Catalyst
- Market update
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1048Tone
finance.yahoo.comDirect company coverage
Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific
Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued in
BiotechGene TherapyGrowth RateMarket Research ReportsMarket ResearchPharmaceuticals
- Published
- 11 Aug 2026 08:45
- Catalyst
- Guidance
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1156Tone
finance.yahoo.comDirect company coverage
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Lakefront Biotherapeutics Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and now includes €50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced its half-year 2026 financial results and provided a second quarter and post-period business upda
BiotechClinical TrialsEarningsFinancial ResultsM AOperating Income
- Published
- 10 Aug 2026 20:01
- Catalyst
- Deals and strategy
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
#1284Tone
finance.yahoo.comDirect company coverage
Key HIV stat over 70% leaves BofA siding with Gilead
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was one of them. The bank reiterated its Buy rating and kept its $162 price target after the report, well above where the stock trades today. One prevention number in particular caught BofA's attention, and it speaks directly to whether Gilead's next growth engine can last. Why Bank of America is standing by Gilead stoc
EarningsFda ApprovalHiv TreatmentOncologyPrice TargetPrice Target
- Published
- 08 Aug 2026 14:07
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Earlier company news
GIS news archive
Stored newest first for historical research. These older headlines are retained for reference and do not contribute to the current sentiment gauge above.
Aug
06
2026
Stock TitanArchivedNeutral tone
Planned 3,000-share sale by Gilead (NASDAQ: GILD) shareholder Johanna Mercier
- Published
- 6 Aug 2026 11:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
03
2026
Stock TitanArchivedNeutral tone
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 plan
- Published
- 3 Aug 2026 06:29
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
30
2026
Stock TitanArchivedNeutral tone
Gilead Sciences (NASDAQ: GILD) exec trades 3,000 shares under 10b5-1 plan
- Published
- 30 Jul 2026 19:05
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
28
2026
TradingKeyArchivedNeutral tone
GILD|Gilead Sciences Inc|Price:129.310|Chg%:-1.550
- Published
- 28 Jul 2026 06:17
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
25
2026
TradingKeyArchivedNeutral tone
GILD|Gilead Sciences Inc|Price:130.840|Chg%:+0.500
- Published
- 25 Jul 2026 19:38
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
18
2026
Stock TitanArchivedNeutral tone
Gilead (NASDAQ: GILD) CEO sells 15,000 shares under 10b5-1 plan
- Published
- 18 Jul 2026 12:27
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
17
2026
Stock TitanArchivedNeutral tone
Gilead Sciences (GILD) CFO sells 3,000 shares in pre-set 10b5-1 trade
- Published
- 17 Jul 2026 16:02
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
07
2026
GuruFocusArchivedNeutral tone
Gilead Sciences Inc (GILD) Stock Up 4.2% but GF Value Says Overv
- Published
- 7 Jul 2026 06:20
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jul
02
2026
AD HOC NEWSArchivedNeutral tone
Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus
- Published
- 2 Jul 2026 22:45
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
27
2026
GuruFocusArchivedNeutral tone
Gilead Sciences Inc (GILD) Shares Surge 3.3% -- What GF Score of 75 Tells Investors
- Published
- 27 Jun 2026 12:28
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
Stock TitanArchivedNeutral tone
Gilead (NASDAQ: GILD) officer sells 3,000 shares under 10b5-1 plan
- Published
- 22 Jun 2026 11:37
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Jun
22
2026
Stock TitanArchivedNeutral tone
Gilead (GILD) CFO exercises 2,796 RSUs and withholds 1,341 shares for taxes
- Published
- 22 Jun 2026 10:41
- Catalyst
- Historical snapshot
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.